Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in reducing itch and rash

NCT ID NCT06727552

Symptom relief Sponsor: Celldex Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests an experimental drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can reduce itching and improve skin condition compared to a placebo. About 131 participants will receive either a low dose, high dose, or placebo over 16 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

131 people

The number who actually took part.

Started

Dec 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female ≥ 18 years of age 2. Diagnosis of chronic atopic dermatitis (AD) for at least 1 year 3. Onset of symptoms at least 1 year prior and current symptoms consistent with moderate to severe AD as defined by: 1. EASI ≥ 12 at Visit 1 and EASI ≥ 16 at Visit 2 2. Body Surface Area of Involvement (BSA) ≥ 10% at Visit 1 and Visit 2 3. IGA score ≥ 3 at Visit 1 and Visit 2 4. Severe itch, defined by weekly average of daily PP-NRS score of ≥ 5, during the 7 days prior to treatment 4. Documented history of inadequate response to treatment with topical medications or for whom topical medications are otherwise medically inadvisable. 5. Willing and able to complete a daily symptom electronic diary for the duration of the study and adhere to the study visit schedule. Exclusion Criteria: 1. Any other active pruritic skin diseases that would confound AD assessments based on the Investigator's clinical judgment. 2. Phototherapy with ultraviolet (UV) A or UVB within 4 weeks of Visit 1. 3. Planned or anticipated use of any prohibited medications at any time during the study. 4. Prior receipt of barzolvolimab or other anti-KIT therapy. There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • 310 Clinical Research

    Inglewood, California, 90301, United States

  • Acclaim Clinical Research

    San Diego, California, 92120, United States

  • Advanced Dermatology Center - Burbank

    Burbank, California, 91506, United States

  • Allergy and Asthma Specialists PSC

    Owensboro, Kentucky, 42301, United States

  • Avance Trials

    Laguna Niguel, California, 92677, United States

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio, 45236, United States

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama, 35244, United States

  • Center for Clinical Studies LTD.LLP

    Webster, Texas, 77598, United States

  • Center for Medical Dermatology + Immunology Research

    Chicago, Illinois, 60657, United States

  • Centricity Research Columbus Dermatology

    Columbus, Georgia, 31904, United States

  • Direct Helpers Research Center

    Hialeah, Florida, 33012, United States

  • Dynasty Dermatology

    Pasadena, California, 91105, United States

  • Equity Medical LLC

    Bowling Green, Kentucky, 42104, United States

  • Equity Medical, LLC

    New York, New York, 10023, United States

  • Excel Clinical Research

    Las Vegas, Nevada, 89109, United States

  • FOMAT Medical Research - Allergy, Asthma, & Immunology Medical Group

    Ventura, California, 93003, United States

  • Focus Clinical Research

    West Hills, California, 91307, United States

  • Georgia Skin and Cancer Clinic

    Savannah, Georgia, 31419, United States

  • International Dermatology Research Inc - Miami

    Miami Lakes, Florida, 33144, United States

  • Jordan Valley Dermatology Center - South Jordan

    South Jordan, Utah, 84095, United States

  • LA Universal Research Center, Inc.

    Los Angeles, California, 90057, United States

  • Ohara Aivaz MD Dermatology

    Beverly Hills, California, 90212, United States

  • Onyx Clinical Research - Michigan

    Flint, Michigan, 48532, United States

  • OptiSkin Medical

    New York, New York, 10128, United States

  • Palmetto Clinical Trial Services LLC

    Simpsonville, South Carolina, 29615, United States

  • Revival Research Institute, LLC

    Troy, Michigan, 48084, United States

  • Sarasota Clinical Research

    Sarasota, Florida, 34233, United States

  • Sienna Dermatology

    Sugar Land, Texas, 77479, United States

  • Sneeze Wheeze and Itch Associates LLC

    Normal, Illinois, 61761, United States

  • Treasure Valley Medical Research

    Boise, Idaho, 83706, United States

  • UCLA Division of Dermatology

    Los Angeles, California, 90089, United States

  • Well Pharma Medical Research Corporation

    South Miami, Florida, 33173, United States

  • Zenos Clinical Research

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.